The Rangers have scratched southpaw Cole Hamels from his start Monday against the Yankees because of left groin soreness, Evan Grant of the Dallas Morning News was among those to report (on Twitter). Hamels also missed a start last year because of a sore groin, but the club doesn’t believe the injury is serious. It’s currently unclear who will start in his place Monday.
More injury updates on some key major leaguers:
- In other news concerning an integral member of the Rangers’ rotation, right-hander Yu Darvish is fully healthy and on track for a mid-May return, general manager Jon Daniels told MLB Network Radio on Sunday (Twitter link). Darvish, who missed the 2015 campaign after undergoing Tommy John surgery, could begin a rehab assignment May 1 and rejoin the Rangers on May 16, Grant wrote earlier this week.
- Another 2015 Tommy John surgery recipient, Rays right-hander Alex Cobb, should return by late July or early August, tweets Marc Topkin of the Tampa Times. Rays closer Brad Boxberger is on course for a mid-May comeback from core muscle surgery, which he underwent in March, adds Topkin.
- Reds righty Anthony DeSclafani, who’s working his way back from an oblique strain, began his rehab stint Saturday at the Double-A level and threw four innings, allowing three runs, four hits and a walk while striking out five. He’ll next start for Low-A Dayton, per Zach Buchanan of the Cincinnati Enquirer (Twitter link). DeSclafani posted a 4.05 ERA with a 7.36 K/9 and 2.68 BB/9 in 184 2/3 innings for the Reds last season.
- Like Darvish and Cobb, Mets lefty Josh Edgin is also coming back from 2015 Tommy John surgery. Edgin’s recovery is going well and it’s possible he’ll return to the majors next month, according to Adam Rubin of ESPN.com. Edgin served as a shutdown option out of the Mets’ bullpen in 2014, compiling a 9.22 K/9 and 1.98 BB/9 to accompany a stingy 1.32 ERA in 27 1/3 innings.
Edgin would be a boost, but I don’t see a clear place for him as it currently stands.
The bullpen as a whole has been excellent, although Blevins has been a tad underwhelming (albeit with a solid FIP in a small sample size). I suppose that Verrett would have to be sent down.